 Crinetics Pharmaceuticals NASDAQ: CRNX recently received a number of ratings updates from brokerages and research firms: 3182020 Crinetics Pharmaceuticals had its overweight rating reaffirmed by analysts at Cantor Fitzgerald. 3172020 Crinetics Pharmaceuticals was downgraded by analysts at BidaskClub from a hold rating to a sell rating. 3162020 Crinetics Pharmaceuticals was downgraded by ... 